FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center.

---

Bengoa S. Y., Ataseven E., Kizmazoglu D., Yenigurbuz F. D., Erdem M., ÖREN H.

Turkish journal of haematology : official journal of Turkish Society of Haematology, cilt.34, sa.1, ss.46-51, 2017 (SCI-Expanded, Scopus, TRDizin)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 34 Sayı: 1
• Basım Tarihi: 2017
• Doi Numarası: 10.4274/tjh.2015.0411
• Dergi Adı: Turkish journal of haematology : official journal of Turkish Society of Haematology
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.46-51
• Anahtar Kelimeler: Relapsed/refractory leukemia, FLAG regimen, Chemotherapy, Childhood
• Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
• Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia.